undefined

Albert Borla

Chairman and CEO of Pfizer discussing the company's pipeline priorities including weight-loss and GLP-1 programs (monthly dosing), acquisitions (Biohaven, Cigen, Metera), loss of exclusivity planning, MFN negotiations, and dividend outlook.

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app